Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring

Molecular Cancer - Tập 21 Số 1 - 2022
Wen Li1, Ji‐Bin Liu2, Likun Hou3, Fei Yu4, Jie Zhang5, Wei Wu3, Xiaomei Tang6, Sun Feng2, Haimin Lu7, Jing Deng1, Jie Bai1, Juan Li1, Chunyan Wu3, Qinlu Lin1, Zhongwei Lv4, Wang Gaoren8, Gengxi Jiang9, Yu‐Shui Ma4, Da Fu6
1National Engineering Research Center of Rice and Byproduct Deep Processing, College of Food Science and Engineering, Central South University of Forestry and Technology, Changsha, 410004, Hunan, China
2Institute of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, 226631, Jiangsu, China
3Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China
4Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China
5Department of Immunology, School of Medicine, Nantong University, Nantong, 226019, Jiangsu, China
6General Surgery, Ruijin Hospital & Institute of Pancreatic Diseases, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
7Department of Thoracic Surgery, Affiliated Tumor Hospital of Nantong University, Nantong, 226631, Jiangsu, China
8Department of Radiotherapy, Affiliated Tumor Hospital of Nantong University, Nantong, 226631, Jiangsu, China
9Department of Thoracic Surgery, Navy Military Medical University Affiliated Changhai Hospital, Shanghai, 200433, China

Tóm tắt

AbstractPrimary lung cancer is one of the most common malignant tumors in China. Approximately 60% of lung cancer patients have distant metastasis at the initial diagnosis, so it is necessary to find new tumor markers for early diagnosis and individualized treatment. Tumor markers contribute to the early diagnosis of lung cancer and play important roles in early detection and treatment, as well as in precision medicine, efficacy monitoring, and prognosis prediction. The pathological diagnosis of lung cancer in small biopsy specimens determines whether there are tumor cells in the biopsy and tumor type. Because biopsy is traumatic and the compliance of patients with multiple biopsies is poor, liquid biopsy has become a hot research direction. Liquid biopsies are advantageous because they are nontraumatic, easy to obtain, reflect the overall state of the tumor, and allow for real-time monitoring. At present, liquid biopsies mainly include circulating tumor cells, circulating tumor DNA, exosomes, microRNA, circulating RNA, tumor platelets, and tumor endothelial cells. This review introduces the research progress and clinical application prospect of liquid biopsy technology for lung cancer.

Từ khóa


Tài liệu tham khảo

de Goede OM, Nachun DC, Ferraro NM, Gloudemans MJ, Rao AS, Smail C, et al. Population-scale tissue transcriptomics maps long non-coding RNAs to complex disease. Cell. 2021;184:2633–48.

Burke M, Rashdan S. Management of Immune-Related Adverse Events in patients with non-small cell lung Cancer. Front Oncol. 2021;11:720759.

Li ZB, Chen DD, He QJ, Li L, Zhou G, Fu YM, et al. The LAC score indicates significant fibrosis in patients with chronic drug-induced liver injury: a large biopsy-based study. Front Pharmacol. 2021;12:734090.

Oliveira MM, Klann E. A deep dive into local mRNA translation in neurons. Proc Natl Acad Sci U S A. 2021;118(45):e2117116118.

Zhao L, Wu X, Zheng J, Dong D. DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution. Oncogene. 2021;40:1884–95.

Dianat-Moghadam H, Mahari A, Heidarifard M, Parnianfard N, Pourmousavi-Kh L, Rahbarghazi R, et al. NK cells-directed therapies target circulating tumor cells and metastasis. Cancer Lett. 2021;497:41–53.

Zhou Q, Geng Q, Wang L, Huang J, Liao M, Li Y, et al. Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: a non-invasive biomarker for predicting malignancy and tumour invasiveness. EBioMedicine. 2019;41:236–43.

Lim M, Park J, Lowe AC, Jeong HO, Lee S, Park HC, et al. A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC. Theranostics. 2020;10(12):5181–94.

Morozov D, Mironov V, Moryachkov RV, Shchugoreva IA, Artyushenko PV, Zamay GS, et al. The role of SAXS and molecular simulations in 3D structure elucidation of a DNA aptamer against lung cancer. Mol Ther Nucleic Acids. 2021;25:316–27.

Bhojnagarwala PS, Perales-Puchalt A, Cooch N, Sardesai NY, Weiner DB. A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation. Mol Ther Oncolytics. 2021;21:278–87.

Zhang X, Yang D, Jiang Y, Huang L, Wang C, Tao D, et al. Comparison of radiation pneumonitis in lung Cancer patients treated with HT versus IMRT and circulating lymphocyte subsets as predicting risk factors. J Inflamm Res. 2021;14:4205–15.

Jiang T, Wang P, Zhang J, Zhao Y, Zhou J, Fan Y, et al. Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial. Signal Transduct Target Ther. 2021;6(1):355.

Singh T, FatehiHassanabad M, FatehiHassanabad A. Non-small cell lung cancer: emerging molecular targeted and immunotherapeutic agents. Biochim Biophys Acta Rev Cancer. 1876;2021(2):188636.

Li X, Li X, Chen S, Wu Y, Liu Y, Hu T, et al. TRAP1 shows clinical significance in the early diagnosis of small cell lung Cancer. J Inflamm Res. 2021;14:2507–14.

Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566(7745):553–7.

Balakrishnan SG, Ahmad MR, Koloor SSR, Petrů M. Separation of ctDNA by superparamagnetic bead particles in microfluidic platform for early cancer detection. J Adv Res. 2021;33:109–16.

Fujisawa R, Iwaya T, Endo F, Idogawa M, Sasaki N, Hiraki H, et al. Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer. Carcinogenesis. 2021;42(10):1239–49.

Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385–9.

Christie JD, Appel N, Canter H, Achi JG, Elliott NM, de Matos AL, et al. Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma. Mol Ther Oncolytics. 2021;22:539–54.

Ramanand SG, Chen Y, Yuan J, Daescu K, Lambros MB, Houlahan KE, et al. The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer. J Clin Invest. 2020;130(8):3987–4005.

Alunni-Fabbroni M, Rönsch K, Huber T, Cyran CC, Seidensticker M, Mayerle J, et al. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J Transl Med. 2019;17(1):328.

Zong Y, Li Q, Zhang F, Xian X, Wang S, Xia J, et al. SDH5 depletion enhances Radiosensitivity by regulating p53: a new method for noninvasive prediction of radiotherapy response. Theranostics. 2019;9(22):6380–95.

Kumaki Y, Olsen S, Suenaga M, Nakagawa T, Uetake H, Ikeda S. Comprehensive genomic profiling of circulating cell-free DNA distinguishes focal MET amplification from aneuploidy in diverse advanced cancers. Curr Oncol. 2021;28(5):3717–28.

Palmisani F, Kovar H, Kager L, Amann G, Metzelder M, Bergmann M. Systematic review of the immunological landscape of Wilms tumors. Mol Ther Oncolytics. 2021;22:454–67.

Alekseeva LA, Sen'kova AV, Zenkova MA, Mironova NL. Targeting circulating SINEs and LINEs with DNase I provides metastases inhibition in experimental tumor models. Mol Ther Nucleic Acids. 2020;20:50–61.

Nicolazzo C, Barault L, Caponnetto S, De Renzi G, Belardinilli F, Bottillo I, et al. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature. Cancer Lett. 2021;507:89–96.

Vasantharajan SS, Eccles MR, Rodger EJ, Pattison S, McCall JL, Gray ES, et al. The epigenetic landscape of circulating tumour cells. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188514.

Chen H, Ma Y, Liu Z, Li J, Li X, Yang F, et al. Circulating microbiome DNA: an emerging paradigm for cancer liquid biopsy. Cancer Lett. 2021;521:82–7.

Buder A, Heitzer E, Waldispühl-Geigl J, Weber S, Moser T, Hochmair MJ, et al. Somatic copy-number alterations in plasma circulating tumor DNA from advanced EGFR-mutated lung adenocarcinoma patients. Biomolecules. 2021;11(5):618.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–51.

Qian H, Zhang Y, Xu J, He J, Gao W. Progress and application of circulating tumor cells in non-small cell lung cancer. Mol Ther Oncolytics. 2021;22:72–84.

Diao Z, Han Y, Zhang R, Li J. Circulating tumour DNA: a new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs. Biochim Biophys Acta Rev Cancer. 1873;2020(2):188363.

Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580(7802):245–51.

Yan JB, Lai CC, Jhu JW, Gongol B, Marin TL, Lin SC, et al. Insulin and metformin control cell proliferation by regulating TDG- mediated DNA demethylation in liver and breast Cancer cells. Mol Ther Oncolytics. 2020;18:282–94.

Ghita M, Copot D, Ionescu CM. Lung cancer dynamics using fractional order impedance modeling on a mimicked lung tumor setup. J Adv Res. 2021;32:61–71.

Heeke S, Hofman V, Benzaquen J, Otto J, Tanga V, Zahaf K, et al. Detection of EGFR mutations from plasma of NSCLC patients using an automatic cartridge-based PCR system. Front Pharmacol. 2021;12:657743.

Le Rhun E, Seoane J, Salzet M, Soffietti R, Weller M. Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. Cancer Lett. 2020;480:24–8.

Decker CJ. The exosome: a versatile RNA processing machine. Curr Biol. 1998;8(7):R238–40.

Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.

Sun J, Lu Z, Fu W, Lu K, Gu X, Xu F, et al. Exosome-derived ADAM17 promotes liver metastasis in colorectal Cancer. Front Pharmacol. 2021;12:734351.

Labani-Motlagh A, Naseri S, Wenthe J, Eriksson E, Loskog A. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes. Mol Ther Oncolytics. 2021;20:508–18.

Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.

Du J, Wan Z, Wang C, Lu F, Wei M, Wang D, et al. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy. Theranostics. 2021;11(17):8185–96.

Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN, et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol. 2013;8(9):1156–62.

Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, et al. Evaluation of tumor-derived Exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung Cancer using next-generation sequencing. Clin Cancer Res. 2017;23(17):5311–9.

Wu H, Mu X, Liu L, Wu H, Hu X, Chen L, et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis. 2020;11(9):801.

Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X, et al. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. Int J Nanomedicine. 2017;12:3721–33.

Liu A, Xie H, Li R, Ren L, Yang B, Dai L, et al. Silencing ZIC2 abrogates tumorigenesis and anoikis resistance of non-small cell lung cancer cells by inhibiting Src/FAK signaling. Mol Ther Oncolytics. 2021;22:195–208.

Yang D, Feng W, Zhuang Y, Liu J, Feng Z, Xu T, et al. Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells. Mol Ther Nucleic Acids. 2021;23:1053–65.

Huber M, Kepesidis KV, Voronina L, Fleischmann F, Fill E, Hermann J, et al. Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer. Elife. 2021;10:e68758.

Baumann K. Making more exosomes. Nat Rev Mol Cell Biol. 2021;22(4):242.

Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell. 2020;182(4):1044–61.

Wu J, Xie Q, Liu Y, Gao Y, Qu Z, Mo L, et al. A small vimentin-binding molecule blocks Cancer exosome release and reduces Cancer cell mobility. Front Pharmacol. 2021;12:627394.

Jiang C, Zhang N, Hu X, Wang H. Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms. Mol Cancer. 2021;20(1):117.

Wu SH, Hsieh CC, Hsu SC, Yao M, Hsiao JK, Wang SW, et al. RBC-derived vesicles as a systemic delivery system of doxorubicin for lysosomal- mitochondrial axis-improved cancer therapy. J Adv Res. 2020;30:185–96.

Viegas ATB, Guedes JR, Oliveira AR, Cardoso AMS, Cardoso ALC. miRNAs: new biomarkers and therapeutic targets in dementia. Curr Pharm Des. 2017;23(5):669–92.

Han Q, Xie QR, Li F, Cheng Y, Wu T, Zhang Y, et al. Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer. Theranostics. 2021;11(13):6526–41.

Pop-Bica C, Pintea S, Magdo L, Cojocneanu R, Gulei D, Ferracin M, et al. The clinical utility of miR-21 and let-7 in non-small cell lung Cancer (NSCLC). A Systematic Review and Meta-Analysis. Front Oncol. 2020;10:516850.

Sun X, Zhang S, Ma X. Prognostic value of MicroRNA-125 in various human malignant neoplasms: a Meta-analysis. Clin Lab. 2015;61(11):1667–74.

Ploeg EM, Ke X, Britsch I, Hendriks MAJM, Van der Zant FA, Kruijff S, et al. Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. Cancer Lett. 2021;521:109–18.

Kakiuchi Y, Kuroda S, Kanaya N, Kumon K, Tsumura T, Hashimoto M, et al. Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles. Mol Ther. 2021;29(10):2920–30.

Hong P, Yu M, Tian W. Diverse RNAs in adipose-derived extracellular vesicles and their therapeutic potential. Mol Ther Nucleic Acids. 2021;26:665–77.

Xu X, Liu Y, Li Y, Chen H, Zhang Y, Liu J, et al. Selective exosome exclusion of miR-375 by glioma cells promotes glioma progression by activating the CTGF-EGFR pathway. J Exp Clin Cancer Res. 2021;40(1):16.

Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2011;481(7380):190–4.

Brown M, Assen FP, Leithner A, Abe J, Schachner H, Asfour G, et al. Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science. 2018;359(6382):1408–11.

Wen ZJ, Xin H, Wang YC, Liu HW, Gao YY, Zhang YF. Emerging roles of circRNAs in the pathological process of myocardial infarction. Mol Ther Nucleic Acids. 2021;26:828–48.

Hu D, Lou X, Meng N, Li Z, Teng Y, Zou Y, et al. Peripheral blood-based DNA methylation of long non-coding RNA H19 and metastasis-associated lung adenocarcinoma transcript 1 promoters are potential non-invasive biomarkers for gastric Cancer detection. Cancer Control. 2021;28:10732748211043667.

Zhang L, Li C, Su X. Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers. J Exp Clin Cancer Res. 2020;39(1):271.

Xiang X, Fu Y, Zhao K, Miao R, Zhang X, Ma X, et al. Cellular senescence in hepatocellular carcinoma induced by a long non-coding RNA-encoded peptide PINT87aa by blocking FOXM1-mediated PHB2. Theranostics. 2021;11(10):4929–44.

Chakraborty C, Sharma AR, Sharma G, Lee SS. Therapeutic advances of miRNAs: a preclinical and clinical update. J Adv Res. 2020;28:127–38.

Meganck RM, Liu J, Hale AE, Simon KE, Fanous MM, Vincent HA, et al. Engineering highly efficient backsplicing and translation of synthetic circRNAs. Mol Ther Nucleic Acids. 2021;23:821–34.

Hang D, Zhou J, Qin N, Zhou W, Ma H, Jin G, et al. A novel plasma circular RNA circFARSA is a potential biomarker for non-small cell lung cancer. Cancer Med. 2018;7(6):2783–91.

Chen T, Liu Y, Li C, Xu C, Ding C, Chen J, et al. Tumor-derived exosomalcircFARSA mediates M2 macrophage polarization via the PTEN/PI3K/AKT pathway to promote non-small cell lung cancer metastasis. Cancer Treat Res Commun. 2021;28:100412.

Cui W, Dang Q, Chen C, Yuan W, Sun Z. Roles of circRNAs on tumor autophagy. Mol Ther Nucleic Acids. 2021;23:918–29.

Bushman FD, Cantu A, Everett J, Sabatino D, Berry C. Challenges in estimating numbers of vectors integrated in gene-modified cells using DNA sequence information. Mol Ther. 2021;S1525–0016(21):00529–3.

Best MG, Wesseling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for Cancer detection and progression monitoring. Cancer Res. 2018;78(13):3407–12.

Best MG, In ‘t veld SGJG, Sol N, Wurdinger T. RNA sequencing and swarm intelligence-enhanced classification algorithm development for blood-based disease diagnostics using spliced blood platelet RNA. Nat Protoc. 2019;14(4):1206–34.

Xing S, Zeng T, Xue N, He Y, Lai YZ, Li HL, et al. Development and validation of tumor-educated blood platelets integrin alpha 2b (ITGA2B) RNA for diagnosis and prognosis of non-small-cell lung Cancer through RNA-seq. Int J Biol Sci. 2019;15(9):1977–92.

Cifarelli V, Appak-Baskoy S, Peche VS, Kluzak A, Shew T, Narendran R, et al. Visceral obesity and insulin resistance associate with CD36 deletion in lymphatic endothelial cells. Nat Commun. 2021;12(1):3350.

Fliney G, Ahmed O, Young B, Teng C, Pointdujour-Lim R. Metastatic Choroidal Melanoma Presenting as Neovascular Glaucoma. Case Rep Ophthalmol. 2021;12(3):791–6.

Carlson JC, Cantu Gutierrez M, Lozzi B, Huang-Hobbs E, Turner WD, Tepe B, et al. Identification of diverse tumor endothelial cell populations in malignant glioma. Neuro-Oncology. 2021;23(6):932–44.

Lei Y, Sun N, Zhang G, Liu C, Lu Z, Huang J, et al. Combined detection of aneuploid circulating tumor-derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non-small-cell lung cancer. Clin Transl Med. 2020;10(3):e128.

Palikuqi B, Nguyen DT, Li G, Schreiner R, Pellegata AF, Liu Y, et al. Adaptable haemodynamic endothelial cells for organogenesis and tumorigenesis. Nature. 2020;585(7825):426–32.

Zhu HH, Liu YT, Feng Y, Zhang LN, Zhang TM, Dong GL, et al. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: predictors for response and prognosis. Thorac Cancer. 2021;12(20):2749–57.

Zhang T, Zhang L, Gao Y, Wang Y, Liu Y, Zhang H, et al. Role of aneuploid circulating tumor cells and CD31+ circulating tumor endothelial cells in predicting and monitoring anti-angiogenic therapy efficacy in advanced NSCLC. Mol Oncol. 2021;15(11):2891–909.